#United States #IDEAYA Biosciences #South San Francisco #Common Stock #Public Offering

IDEAYA Biosciences Plans a Major Public Offering

IDEAYA Biosciences, Inc., headquartered in South San Francisco, has made a significant announcement—it's preparing to offer up to $300 million in shares of its common stock as part of a public offering aimed at funding its innovative cancer therapies. This move represents a pivotal step for the company as it continues to advance its mission in precision medicine oncology.

In addition to the stock offering, IDEAYA is also providing certain investors with the opportunity to acquire pre-funded warrants that can be exercised to purchase its common stock. These pre-funded warrants may provide liquidity for investors and facilitate quicker access to shares, aligning with the company's strategic funding goals.

To further bolster its offering, IDEAYA plans to give underwriters the option to purchase an additional $45 million in common stock within a 30-day period. This provision is designed to meet the potential demand from investors and to optimize the funds raised during this offering.

The offering is contingent upon various market conditions and factors, and as such, IDEAYA has cautioned that there are no guarantees regarding the completion or terms of the offering. The banks engaged in this vital financial maneuver include J.P. Morgan, Jefferies , TD Cowen, UBS Investment Bank, and Cantor, who are acting as joint book-running managers.

This public offering is made possible through an automatically effective shelf registration statement initially filed with the U.S. Securities and Exchange Commission (SEC). Prospective investors can obtain detailed information about the offering via a prospectus that will be furnished as part of this process. IDEAYA emphasizes that interested parties should review the preliminary prospectus supplement and accompanying prospectus that will be filed with the SEC, highlighting the terms of the offering.

As IDEAYA pushes forward in its endeavors, compliance with securities laws is paramount; hence, this release serves as an informational notice and does not constitute an offer to sell or a solicitation of offers to buy the securities in states where such sales would be unlawful.

About IDEAYA Biosciences

IDEAYA is devoted to delivering transformative therapies in the field of oncology. By utilizing a combination of small-molecule drug discovery and cutting-edge structural biology, IDEAYA is at the forefront of developing targeted cancer treatments. Their precision medicine approach is greatly enhanced by employing translational biomarker identification and verification, ensuring that therapies are tailored to individual patient needs.

The company's product pipeline emphasizes a strong focus on synthetic lethality and antibody-drug conjugates designed for specific solid tumor indications. Their goal is to introduce a new generation of precision oncology therapies, offering more selective and effective treatments that aim to meaningfully improve the odds for cancer patients.

Looking Forward

As IDEAYA continues on its path of discovery and development, it must navigate potential risks and uncertainties that could affect its operations and the success of this public offering. These include market conditions that could impact the ability to complete the offering as planned, alongside challenges inherent in the drug development process, such as conducting clinical trials and gaining market approval.

In closing, IDEAYA remains committed to its mission of advancing personalized cancer treatment. The upcoming public offering represents a critical step in that journey, with the potential to enhance the company’s capabilities and ultimately benefit patients facing cancer therapies. Stakeholders and market watchers will certainly be paying close attention as the situation evolves and more information becomes available.